Zimmer Biomet’s (ZBH) Hold Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Zimmer Biomet (NYSE:ZBH) in a report released on Tuesday morning,Benzinga reports.

A number of other research firms have also recently weighed in on ZBH. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Johnson Rice set a $112.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, November 5th. Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Finally, Barclays dropped their price objective on shares of Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $106.10.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $91.54 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. Zimmer Biomet has a one year low of $84.59 and a one year high of $114.44. The company has a 50-day simple moving average of $89.97 and a 200-day simple moving average of $95.64. The stock has a market capitalization of $18.14 billion, a price-to-earnings ratio of 22.66, a PEG ratio of 2.29 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period last year, the company earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, analysts predict that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

Hedge Funds Weigh In On Zimmer Biomet

Institutional investors have recently added to or reduced their stakes in the company. Key Financial Inc increased its stake in Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. raised its stake in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC lifted its holdings in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares during the last quarter. Root Financial Partners LLC acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $31,000. Finally, Flagship Harbor Advisors LLC bought a new position in Zimmer Biomet during the 4th quarter worth $32,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 EPS beat: Zimmer reported $2.42 EPS vs. $2.38 consensus and revenue of $2.24B (vs. $2.22B), with sales up 10.9% year-over-year — a clear near-term growth signal. ZBH Q4 Earnings & Revenues Top Estimates
• Positive Sentiment: Procedure-driven demand: Reuters notes strong demand for hips and knees helped drive the beat — positive for organic growth and market share in core device categories. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Positive Sentiment: Analyst bullishness: BTIG reaffirmed a “buy” rating and set a $112 price target (~22% above the current price), which can support upside as investors re-price the stock. Benzinga
• Neutral Sentiment: FY-2026 guidance roughly in line but slightly cautious: management guided EPS to $8.30–$8.45 (consensus ~$8.44) and revenue to $8.4–$8.6B (consensus ~$8.6B), so guidance doesn’t materially exceed Street expectations. Press Release
• Neutral Sentiment: Analyst mix: Needham and other outlets reiterated a “hold”/consensus “hold,” signaling varied analyst views — creates both supporters and skeptics around the shares. Benzinga
• Neutral Sentiment: Broader coverage and previews: Multiple outlets (Zacks, MSN) highlighted the quarter and key metrics — increases visibility but not a directional catalyst by itself. What to expect from Zimmer Biomet’s (ZBH) Q4 earnings
• Negative Sentiment: Margin pressure: Coverage notes margin contraction despite the top-line beat — investors may watch margin trajectory closely, as margin compression can limit upside to profitability and valuation. ZBH Q4 Earnings & Revenues Top Estimates

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.